YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas

Keyphrases

• Active Disease 9%
• Anaplastic Astrocytoma 9%
• Anaplastic Glioma 18%
• Differentially Expressed 9%
• Glioblastoma multiforme 27%
• Glioma 9%
• Glioma Patients 27%
• Hazard Ratio 27%
• High-grade Glioma 100%
• Inverse Association 9%
• Magnetic Resonance Imaging Scan 9%
• Malignant Glioma 9%
• Matrix metalloproteinase-9 (MMP-9) 100%
• Patient Demographics 9%
• Patient Serum 9%
• Patients with Cancer 9%
• Postoperative Period 9%
• Prospective Longitudinal Study 9%
• Serum Biomarkers 100%
• Serum Levels 9%
• Serum Markers 9%
• Serum Samples 18%
• Surgical Resection 9%
• Survival Prediction 9%
• Treatment Response 9%
• Tumor 27%
• YKL-40 100%

Neuroscience

• Astrocytoma 14%
• ELISA 14%
• Epileptic Absence 14%
• Glioblastoma Multiforme 42%
• Longitudinal Study 14%
• Magnetic Resonance Imaging 14%
• MMP9 100%